16 results on '"Mehmet Ali Uçar"'
Search Results
2. P1073: A NEW SCORING SYSTEM TO PREDICT SURVIVAL IN ELDERLY ADVANCED STAGE HODGKIN LYMPHOMA PATIENTS: STUDY BY TURKISH SOCIETY OF HAEMATOLOGY LYMPHOMA ACADEMY WORKING GROUP
- Author
-
Özgür Mehtap, Tayfur Toptas, Mehmet Sinan Dal, Güner Hayri Özsan, Nigün Sayinalp, Güray Saydam, Mehmet Ali Uçar, Hakki Onur Kirgizlar, Ozan Salim, Atakan Tekinalp, Fahir Özkalemkaş, Funda Pepedil Tanrikulu, Olga Meltem Akay, Emrah Kiliçaslan, Semra Paydas, Sinem Civriz, Mehmet Yilmaz, Volkan Karakuş, Fatma Geçgel, Tahir Darçin, Elçin Erdoğan, Erkin Çinar, Fatma Keklik Karadağ, Ünal Ataş, Vildan Gürsoy, Salih Sertaç Durusoy, Elif Birtaş Ateşoğlu, Anil Tombak, Nurhilal Büyükkurt, Muhit Özcan, Fevzi Altuntaş, and Ahmet Burhan Ferhanoğlu
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
3. Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels
- Author
-
Funda Ceran, Sema Akıncı, Mehmet Ali Uçar, Gülten Korkmaz, Mehmet Gündüz, Büşranur Çavdarlı, Şule Mine Bakanay, Mesude Falay, Simten Dağdaş, İmdat Dilek, and Gülsüm Özet
- Subjects
chronic myeloid leukemia ,bcr: : abl1 is ,halving time ,reduction ratio ,molecular response ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Objective: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR: : ABL1 transcript levels have recently emerged as additional prognostic indexes besides the BCR: : ABL1 International Scale (IS). We aimed to investigate the prognostic role of BCR: : ABL1 transcript levels, HT, and RR on molecular response kinetics at 3 months in patients with newly diagnosed chronic-phase (CP)-CML. Materials and Methods: Forty patients with CP-CML who received first-line imatinib treatment were included in this study. BCR: : ABL1 transcript levels and molecular responses at baseline and at 3, 6, 12, and 24 months of treatment were evaluated retrospectively. Major molecular response (MMR) at 12 months and event-free survival (EFS) were determined as primary endpoints and the effects of treatment kinetics on these parameters were examined. Results: Of the 40 patients, BCR: : ABL1 IS was ≤10% at 3 months in 72.5%, representing EMR. The rate of event occurrence was 45.5% in patients with BCR: : ABL1 IS of >10%, whereas it was 6.9% in those with BCR: : ABL1 IS of ≤10% (p=0.004). MMR was detected in 62.1% of the patients with EMR and in 9.1% of those without EMR (p=0.003). The cut-off value for achieving MMR was 24 days for HT and 0.04 for RR. Deep molecular response (DMR) at 24 months was associated with HT of ≤24 days and RR of ≤0.04. EFS was found to be significantly better in the group with BCR: : ABL1 IS of ≤10% and HT of ≤24 days (p=0.001) and in the group with BCR: : ABL1 IS of ≤10% and RR of ≤0.04 (p=0.007) compared to others. Conclusion: Our findings revealed that MMR could be predicted via EMR as well as by HT and RR. Additionally, HT of ≤24 days and RR of ≤0.04 were more important than BCR: : ABL1 IS of ≤10% in achieving DMR at 24 months, and the combination of BCR: : ABL1 IS of ≤10% with both HT of ≤24 days and RR of ≤0.04 has the best predictive value for EFS.
- Published
- 2022
- Full Text
- View/download PDF
4. Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
- Author
-
Anıl Tombak, Funda Pepedil Tanrıkulu, Salih Sertaç Durusoy, Hüseyin Derya Dinçyürek, Emin Kaya, Elif Gülsüm Ümit, İrfan Yavaşoğlu, Özgür Mehtap, Burak Deveci, Mehmet Ali Özcan, Hatice Terzi, Müfide Okay, Nilgün Sayınalp, Mehmet Yılmaz, Vahap Okan, Alperen Kızıklı, Ömer Özcan, Güven Çetin, Sinan Demircioğlu, İsmet Aydoğdu, Güray Saydam, Eren Arslan Davulcu, Gül İlhan, Mehmet Ali Uçar, Gülsüm Özet, Seval Akpınar, Burhan Turgut, İlhami Berber, Erdal Kurtoğlu, Mehmet Sönmez, Derya Selim Batur, Rahşan Yıldırım, Vildan Özkocaman, Ahmet Kürşad Güneş, Birsen Sahip, Şehmus Ertop, Olga Meltem Akay, Abdülkadir Baştürk, Mehmet Hilmi Doğu, Aydan Akdeniz, Ali Ünal, Ahmet Seyhanlı, Emel Gürkan, Demet Çekdemir, and Burhan Ferhanoğlu
- Subjects
lymphocytic leukemia ,ibrutinib ,bruton's tyrosine kinase inhibitor ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +- standard deviation: 64.6+-10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed. Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p
- Published
- 2021
- Full Text
- View/download PDF
5. Changes in sleep quality and geriatric-8 (G8) score with chemotherapy in older patients with multiple myeloma
- Author
-
Mahmut Bakır Koyuncu, Çağatay Çavuşoğlu, Anıl Tombak, Mehmet Ali Uçar, Aydan Akdeniz, and Eyüp Naci Tiftik
- Subjects
multiple myeloma ,sleep quality ,geriatric scores ,multiple myelom ,uyku kalitesi ,geriatrik değerlendirme ,Medicine (General) ,R5-920 - Abstract
Purpose: The aim of this study was to evaluate the sleep quality of older patients with multiple myeloma before and after chemotherapy and investigate factors affecting sleep quality. Materials and Methods: A total of 108 patients with newly diagnosed multiple myeloma were included in the study. Geriatric 8 (G8) and Pittsburgh Sleep Quality Index scores were calculated for the patients at the time of diagnosis, and the changes in these scores were evaluated after three cycles of chemotherapy. Results: At the time of diagnosis, 63 (58.3%) of the patients had sleep disturbances. The sleep disturbance rate decreased to 41.7% after chemotherapy. There was no statistically significant difference in the total G8 score before and after treatment. In logistic regression analyses, the serum calcium level, pre-treatment G8 score, and response to chemotherapy were predictors of sleep quality. Increases in sleep quality were significantly higher in patients with good responses to chemotherapy. Conclusion: Sleep disturbances are a common problem in older patients with multiple myeloma. Our study demonstrated that sleep quality increased with chemotherapy, and patients with low sleep quality had worse responses to treatment. Therefore, there is a need for measures and treatments to increase the sleep quality of these patients.
- Published
- 2021
6. Polisitemi Veralı Hastalarda Dinamik Thiol/Disulfit Dengesi ve İskemi Modifiye Albumin Düzeyleri
- Author
-
Özcan Erel, Hakan Basir, Mustafa Ilgan, Eyüp Naci Tiftik, Mahmut Bakır Koyuncu, Mehmet Ali Uçar, Aydan Akdeniz, Anıl Tombak, and Salim Neşelioğlu
- Subjects
disulfit ,polistemi vera ,oksidatif stres ,tiyol ,disulfide ,polycythemia vera ,oxidative stress ,thiol ,Medicine ,Medicine (General) ,R5-920 - Abstract
Aim: Polycythemia vera is a chronic myeloproliferative disease characterized by increased red cell mass and JAK2 mutation positivity. Transformation to myelofibrosis and acute leukemia is possible in patients with polycythemia vera. Oxidative stress causes DNA damage and might be a reason for malignant transformation. Thiol molecules can prevent the harmful effects of oxidative stress. Therefore, in this study, we aimed to analyze the state of thiol homeostasis in patients with polycythemia vera. Material and Methods: Thirty-one patients with polycythemia vera and 80 healthy volunteers were included in this study. Serum samples of the cases were stored until the end of the study. Native thiol, total thiol, disulfide, and ischemia modified albumin levels were determined. Results: The mean ischemia modified albumin (1.09±0.21 vs 0.67±0.08; p
- Published
- 2021
- Full Text
- View/download PDF
7. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study
- Author
-
Anıl Tombak, Mehmet Ali Uçar, Aydan Akdeniz, Eyüp Naci Tiftik, Deniz Gören Şahin, Olga Meltem Akay, Murat Yıldırım, Oral Nevruz, Cem Kis, Emel Gürkan, Şerife Medeni Solmaz, Mehmet Ali Özcan, Rahşan Yıldırım, İlhami Berber, Mehmet Ali Erkurt, Tülin Fıratlı Tuğlular, Pınar Tarkun, İrfan Yavaşoğlu, Mehmet Hilmi Doğu, İsmail Sarı, Mustafa Merter, Muhit Özcan, Esra Yıldızhan, Leylagül Kaynar, Özgür Mehtap, Ayşe Uysal, Fahri Şahin, Ozan Salim, and Mehmet Ali Sungur
- Subjects
azacitidine ,acute myeloid leukemia ,elderly ,bone marrow blasts ,prognostic factors ,overall survival ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Objective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective multicenter study, 130 patients of ≥60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included. Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment.nMedian overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of
- Published
- 2016
- Full Text
- View/download PDF
8. Correlation between Haller index and echocardiographic and spirometric findings in children with pectus excavatum
- Author
-
Alper Hazım Gürsu, Barbaros Şahin Karagün, Özlem Korkmaz, Sarper Şükrü Gürsu, and Mehmet Ali Uçar
- Subjects
funnel chest ,transthoracic echocardiography ,respiratory function tests. ,Medicine ,Internal medicine ,RC31-1245 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Objectives: In this study, we evaluated the correlation between severity of deformity and cardiopulmonary function with regards to echocardiographic and spirometric findings. Study design: Twenty-five children, mean age 13.6 years, presenting with pectus excavatum between August 2012 and May 2013, were included. Haller index (HI) was calculated for each patient. Patients with an index of 3.6 as Group 3. Left ventricle dimension, ejection fraction, and shortening fraction were evaluated with echocardiography. Using spirometry, forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and FEV1/FVC ratio were calculated. Groups were compared using these parameters. Results: There were 18 males and 7 females. The mean index was 3.48+-0.78. Though there was no significant difference in the index with regards to sex, the index increased with age. Eight percent of patients were in Group 1, 52% in Group 2 and 40% in Group 3. A significant decrease in ejection and shortening fractions was evident as the index increased. A statistically significant relation between HI and cardiac dysfunction was evident (p
- Published
- 2014
- Full Text
- View/download PDF
9. Clinical Characteristics and Outcomes of Cancer Cases Among Syrian Refugees From Southern Turkey
- Author
-
Tezer Kutluk, Berksoy Şahin, Meral Kirazlı, Fahad Ahmed, Sinem Aydın, Havva Yeşil Çınkır, Gülay Sezgin, İbrahim Bayram, Senar Ebinç, Abdurrahman Işıkdoğan, İlgen Şaşmaz, Vahap Okan, Gül İlhan, Ayşe Ceyda Ören, Sinan Akbayram, Hakan Harputluoğlu, Cihan Ural, Orhan Ayyıldız, Gökmen Aktaş, Mehmet Ali Uçar, Birol Güvenç, Doğan Köse, Can Acıpayam, Sabri Güncan, Vehbi Erçolak, İlhami Berber, Aydan Akdeniz, Arzu Akyay, Veysiye Hülya Üzel, Murat Söker, Meltem Şengelen, Şuayib Yalçın, and Richard Sullivan
- Subjects
General Medicine - Abstract
ImportanceCancer was a common noncommunicable disease in Syria before the present conflict and is now a major disease burden among 3.6 million Syrian refugees in Turkey. Data to inform health care practice are needed.ObjectiveTo explore sociodemographic characteristics, clinical characteristics, and treatment outcomes of Syrian patients with cancer residing in the southern border provinces of Turkey hosting more than 50% of refugees.Design, Setting, and ParticipantsThis was a retrospective hospital-based cross-sectional study. The study sample consisted of all adult and children Syrian refugees diagnosed and/or treated for cancer between January 1, 2011, and December 31, 2020, in hematology-oncology departments of 8 university hospitals in the Southern province of Turkey. Data were analyzed from May 1, 2022, to September 30, 2022.Main Outcomes and MeasuresDemographic characteristics (date of birth, sex, and residence), date of first cancer-related symptom, date and place of diagnosis, disease status at first presentation, treatment modalities, date and status at last hospital visit, and date of death. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision and International Classification of Childhood Cancers, Third Edition, were used for the classification of cancer. The Surveillance, Epidemiology, and End Results system was applied for staging. The diagnostic interval was defined as the number of days from first symptoms until the diagnosis. Treatment abandonment was documented if the patient did not attend the clinic within 4 weeks of a prescribed appointment throughout the treatment.ResultsA total of 1114 Syrian adult and 421 Syrian children with cancer were included. The median age at diagnosis was 48.2 (IQR, 34.2-59.4) years for adults and 5.7 (IQR, 3.1-10.7) years for children. The median diagnostic interval was 66 (IQR, 26.5-114.3) days for adults and 28 (IQR, 14.0-69.0) days for children. Breast cancer (154 [13.8%]), leukemia and multiple myeloma (147 [13.2%]), and lymphoma (141 [12.7%]) were common among adults, and leukemias (180 [42.8%]), lymphomas (66 [15.7%]), and central nervous system neoplasms (40 [9.5%]) were common among children. The median follow-up time was 37.5 (IQR, 32.6-42.3) months for adults and 25.4 (IQR, 20.9-29.9) months for children. The 5-year survival rate was 17.5% in adults and 29.7% in children.Conclusions and RelevanceDespite universal health coverage and investment in the health care system, low survival rates were reported in this study for both adults and children with cancer. These findings suggest that cancer care in refugees requires novel planning within national cancer control programs with global cooperation.
- Published
- 2023
10. Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving time of BCR: : ABL1 IS Transcript Levels
- Author
-
Funda Ceran, Sema Akıncı, Mehmet Ali Uçar, Gülten Korkmaz, Mehmet Gündüz, Büşranur Çavdarlı, Şule Mine Bakanay, Mesude Falay, Simten Dağdaş, İmdat Dilek, and Gülsüm Özet
- Subjects
Hematology - Published
- 2022
11. Düşük riskli miyelodisplastik sendrom hastalarında proksismal noktürnal hemoglobinüri klon varlığının değerlendirilmesi
- Author
-
Mehmet Ali Uçar
- Subjects
Myelodisplastik sendrom,paroksismal nokturnal hemoglobinüri,klonalite ,Health Care Sciences and Services ,General Medicine ,Sağlık Bilimleri ve Hizmetleri - Abstract
Aim: Myelodysplastic syndrome (MDS) is a clonal stem celldisease of bone marrow characterized by dysplasia of hematopoietic precursorcells in bone marrow. Paroxysmal nocturnal hemoglobinuria (PNH) is alife-threatening, clonal, non-malignant hematopoietic stem cell disease of thebone marrow. This study was planned to evaluate both PNH clone level andfrequency in patients with low-risk MDS. Methods:The normal distribution of the data was evaluated by Kolmogorov-Smirnov test.Normal distribution of numerical variables was expressed as mean ± standarddeviation, and categorical variables were expressed as number and percentage. Differences ofnumerical variables according to the presence of PNH were evaluated by StudentT test and Mann Whitney U test. Myelodysplastic syndrome patients followed upin Mersin University Medical Faculty Hematology Department between 2010-2019were included in the study. Results:The study consisted of 13 patients with PNH clones and 176 total 189 MDSpatients without PNH clones. The rate of patients with PNH clone was 7%.The mean age of the patients was 64.5 ± 13 years, female rate was 51.8%, and therate of hypocellularity of bone marrow was higher (61.5% vs 16.5%; p = 0.001). Decreasedhematocrit levels increased lactic dehydrogenase ratio, increased revisedinternational prognostic score were identified as possible risk factorsassociated with mortality compared to those without PNH clones. Conclusion: In the presence of ahypocellular bone marrow in some of the low-risk MDS patients, PNH cloneanalysis is recommended for patients who go with refractory anemia withoutblast increase, and PNH clone analysis if cytopenia is accompanied by high LDH., Amaç:Miyelodisplastik sendrom (MDS) kemik iliğinde hematopoetik öncül hücrelerindisplazisi sonucu sitopenilerle karakterize kemik iliğinin klonal kök hücrehastalığıdır. Kemik iliğinde eritrositik, megakaryositik ve granülositikserilerin her üçü de etkilenebilir. Paroksismal nokturnal hemoglobinüri (PNH)hayatı tehdit edici, kemik iliğinin klonal, malign olmayan hematopoetik kökhücre hastalığıdır. Düşük riskli MDS tanısına sahip hastalarda hem PNH klondüzeyi ve sıklığını değerlendirmek üzere bu çalışma planlanmıştır. Yöntem:Çalışma retrospektifgözlemsel çalışma olarak planalndı. Verilerinnormal dağılımı Kolmogorov-Smirnov testi ile değerlendirildi. Sayısaldeğişkenlerden normal dağılım sergileyenler ortalama±standart sapma olarak,kategorik değişkenler sayı ve yüzde olarak belirtildi. PNH varlığına göresayısal değişkenlerin farklılığı Studen T testi ve Mann Whitney U iledeğerlendirildi. Mortalite ile ilişkili bulgular univariable Cox regressionanaliz ile değerlendirildi. 2010-2019 yılları arasında Mersin Üniversitesi TıpFakültesi Hematoloji BD’da takipli myelodisplastik sendrom hastaları çalışmayaalındı. Bulgular:Araştırma PNH klonu olan 13 hasta ve PNH klonu olmayan 176 toplam 189 MDShastasından oluştu. PNH klonuna sahip hasta oranı %7 olarak saptandı.Hastaların ortalama yaşı 64.5±13 yıl, kadın oranı %51.8, PNH klonu olanlardaolmayanlara kıyasla kemik iliğinin hiposellülerite oranı yüksek (%61.5 vs%16.5; p=0.001) saptandı. PNH klonu olanlarda olmayanlara kıyasla azalanhematokrit düzeyi, artan laktik dehidrogenaz oranı, artan revize edilmişuluslararası prognositik skoru mortalite ile ilişki gösteren olası riskfaktörleri olarak belirlenmiştir. Sonuç:Düşük riskli MDS hastalarının bir kısmında görülen hiposellüler bir kemik iliğivarlığında, blast artışı olmayan refrakter anemi ile giden hastalara PNH klonanalizi yapılması, sitopeni tablosuna yüksek LDH eşlik etmesi halinde PNH klonanalizi önerilmektedir.
- Published
- 2019
12. The effect of smoking and other risk factors on thrombosis in patients with polycythemia vera living in Mersin region
- Author
-
Mehmet Ali Uçar
- Abstract
GİRİŞ: Polisitemia vera (PV) miyeloproliferatif neoplaziler arasında yer alan, başta eritroid seri olmak üzere değişken oranda kan hücrelerinin kontrolsüz çoğalması ve total kan volümünün mutlak artışı ile karakterize, kronik, klonal bir hastalıktır. Prognoz, klinik seyir sırasında ortaya çıkan komplikasyonların ciddiyetine bağlıdır. PV’de, morbidite ve mortalitenin ana nedenini, aynı zamanda tedavi seçeneğini de belirleyen trombotik komplikasyonlar oluşturur. Bu çalışma Mersin bölgesinde polistemia veralı hastalarda, çevresel ve genetik tromboembolik komplikasyon riskini belirlemeye yönelik olarak planlanmıştır. MATERYAL VE METOD: Mersin Üniversitesi Tıp Fakültesi Hastanesinde 2009 ve 2017 yılları arasında dünya sağlık örgütünün belirlemiş olduğu 2001-2008 kriterlerine uygun olarak belirlen polisitemia vera tanısı almış olan 102 hastanın medikal kayıtları incelendi. Hastaların demografik ve klinik verileri, geçirilmiş trombotik olaylar, tanı anındaki laboratuar verileri, retrospektif olarak değerlendirildi. JAK2V617F mutyasonu geleneksel metodlara göre tarandı. BULGULAR: Araştırma popülasyonu 102 PV tanılı hastadan oluşmaktadır, 49’i trombotik olay öyküsü olmayan, 53’u ise trombotik olay öyküsü olan gruptan oluşmakta idi. Trombotik olay öyküsü olan hastalarda yaş yüksek saptandı. Trombotik olay öyküsü olan hastalarda olmayanlara kıyasla HT, kalp hastalığı varlığı, sigara kullanımı ve JAK-2 V617F mutasyon varlığı arasında istatistiksel olarak anlamlı bir ilişki saptandı (p
- Published
- 2019
13. Mersin Bölgesinde Yaşayan Yüksek Riskli Myelodisplastik Sendrom Hastalarında Kronik Hastalık Varlığının Sağ Kalım Üzerine Etkisi
- Author
-
Mehmet Ali Uçar
- Subjects
COPD ,medicine.medical_specialty ,Cytopenia ,Hematology ,business.industry ,Proportional hazards model ,Myelodysplastic syndrome,chronic disease,prognosis ,myelodisplastik sendrom,kronik hastalık ,Disease ,medicine.disease ,Single Center ,Tıp ,Internal medicine ,medicine ,Risk of mortality ,Outpatient clinic ,Medicine ,business - Abstract
Aim:Myelodysplasticsyndrome is a clonal stem cell disease of the hematopoietic system.Myelodysplastic syndrome is a more common disease in men over 65 years of age.Prognosis is determined by the addition of cytogenetic examination, bone marrowblast number and degree of cytopenia and the International Prognosis ScoringSystem (IPSS). This study was planned to determine the effect of chronicdiseases on survival and prognostic value in patients with high riskmyelodysplastic syndrome.Method: Between January 2011 and January 2019, patientsdiagnosed with MDS in the Hematology outpatient clinic of Mersin UniversityMedical Faculty were evaluated retrospectively. A total of 124 patients aged18-96 years, who were present before or at the time of diagnosis of chronic disease,were diagnosed as MDS by bone marrow biopsy. Categorical variables wereexpressed as numbers and percentages. Mortality-related findings were evaluatedby univariable Cox regression analysis.Results: The mean age of the patients was 67 years.Cardiac disease, cerebrovascular disease, cancer and chronic obstructivepulmonary disease were identified as possible risk factors increasing themortality risk. It was found that increasing age 1 year increased the risk ofmortality 1.03 times. Those with cardiac disease had a 1.60-fold mortality riskcompared to those without. Those with COPD had a 1.78-fold mortality riskcompared to those without..Conclusion: Advanced age, cardiac disease,cerebrovascular disease, cancer and chronic obstructive pulmonary disease wereidentified as possible risk factors that increased mortality. This study isimportant because it is the first study with the highest number of patientswith single center in Mersin region on MDS. However, we think that these datawill shed light on the effect of the presence of chronic disease on mortalityand the most appropriate treatment options in MDS patients living in Mersin., Amaç: Myelodisplastik sendrom hematopoetik sistemin klonal kök hücrehastalığıdır. Myelodisplastik sendrom, 65 yaş üzerinde erkeklerde daha sıkgörülen bir hastalıktır. Prognoz tayininde sitogenetik inceleme, kemikiliğindeki blast sayısı ve sitopeninin derecesinin eklenmesi ile UluslarasıPrognoz Puanlama Sistemi (IPSS) kullanılır. Yüksek riskli myelodisplastik sendromhastalarında kronik hastalıkların sağ kalım üzerine etkisi ve prognostikdeğerini tespit etmek üzere bu çalışma planlandı.Yöntem: 2011 ocak ve 2019 ocak yılları arasında Mersin Üniversitesi TıpFakültesi Hematoloji polikliniğinde MDS tanılı hastalar retrospektif olarakdeğerlendirildi. 18-96 yaş arası, kronik hastalık varlığı tanı anında veyaöncesinde mevcut olan, kemik iliği biyopsisi ile MDS tanısı konan 124 hastaçalışmaya alındı. Kategorik değişkenler sayı ve yüzde olarak belirtildi.Mortalite ile ilişkili bulgular univariable Cox regression analiz iledeğerlendirildi.Bulgular: Hastaların ortalama yaşı 67 yıldı. Kardiyak hastalık, serebrovaskülerhastalık, kanser ve kronik obstruktif akciğer hastalığı mortalite riskiniarttıran olası risk faktörleri olarak saptandı. Yaşın 1 yıl artması 1,03 katmortalite riskini arttırdığı saptandı. Kardiyak hastalığı olanlar olmayanlarakıyasla 1,60 kat mortalite riskine sahipti. KOAH olanlar olmayanlara kıyasla1,78 kat mortalite riskini sahipti. Sonuç: İleri yaş, kardiyak hastalık, serebrovasküler hastalık, kanser vekronik obstruktif akciğer hastalığı mortalite riskini arttıran olası riskfaktörleri olarak saptandı. Bu çalışma MDS üzerine Mersin bölgesinden yapılmıştek merkezli en fazla hasta sayısına sahip olan ilk çalışma olması nedeni ileönemlidir. Bununla birlikte elde ettiğimiz bu verilerin Mersin’de yaşayan MDShastalarında kronik hastalık varlığının mortaliteye etkisi ve en uygun tedaviseçeneklerini belirlemeye ışık tutacağını düşünmekteyiz.
- Published
- 2019
14. Prognostic Significance of MIPI and MIPI-B Scoring Systems for Mantle Cell Lymphoma in the Turkish Population
- Author
-
Mehmet Ali, Uçar, primary, Simten, Dağdaş, additional, Murat, Albayrak, additional, Osman, şahin, additional, Funda, Ceran, additional, Mesude, Falay, additional, and Gülsüm, özet, additional
- Published
- 2019
- Full Text
- View/download PDF
15. Correlation between Haller index and echocardiographic and spirometric findings in children with pectus excavatum
- Author
-
Barbaros Şahin Karagün, Sarper Sükrü Gürsu, Mehmet Ali Uçar, Alper Hazım Gürsu, and Ozlem Korkmaz
- Subjects
Male ,Spirometry ,Vital capacity ,medicine.medical_specialty ,lcsh:Internal medicine ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Adolescent ,Vital Capacity ,lcsh:Medicine ,Severity of Illness Index ,Cohort Studies ,FEV1/FVC ratio ,Pectus excavatum ,Forced Expiratory Volume ,Internal medicine ,Deformity ,Humans ,Medicine ,Child ,lcsh:RC31-1245 ,transthoracic echocardiography ,respiratory function tests ,Ejection fraction ,medicine.diagnostic_test ,business.industry ,lcsh:R ,medicine.disease ,funnel chest ,medicine.anatomical_structure ,Echocardiography ,Ventricle ,lcsh:RC666-701 ,Cardiology ,Female ,Haller index ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
Objectives: In this study, we evaluated the correlation between severity of deformity and cardiopulmonary function with regards to echocardiographic and spirometric findings. Study design: Twenty-five children, mean age 13.6 years, presenting with pectus excavatum between August 2012 and May 2013, were included. Haller index (HI) was calculated for each patient. Patients with an index of 3.6 as Group 3. Left ventricle dimension, ejection fraction, and shortening fraction were evaluated with echocardiography. Using spirometry, forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and FEV1/FVC ratio were calculated. Groups were compared using these parameters. Results: There were 18 males and 7 females. The mean index was 3.48+-0.78. Though there was no significant difference in the index with regards to sex, the index increased with age. Eight percent of patients were in Group 1, 52% in Group 2 and 40% in Group 3. A significant decrease in ejection and shortening fractions was evident as the index increased. A statistically significant relation between HI and cardiac dysfunction was evident (p
- Published
- 2014
16. İMMÜN TROMBOSİTOPENİDE BİR RİSK FAKTÖRÜ OLARAK KADIN CİNSİYETİN ROLÜ.
- Author
-
Berna Nur Karataş and Mehmet Ali Uçar
- Abstract
Giriş: İmmün trombositopeni (İTP), trombositlere karşı oluşan otoantikorların trombositopeni yapması ile seyreden edinsel bir hastalıktır. Tanısı trombositopeni yapan diğer nedenler dışlanarak konulmaktadır. Klinikte kanama bulguları olabilir. Bu bulgular genellikle ekimoz, peteşi, epitaksis, menoraji ve diş eti kanaması şeklindedir. İTP' de farklı tedaviler mevcuttur ancak birinci sırada genellikle steroid verilmektedir. Biz bu çalışmamızda İTP hastalarının klinik süreçlerini retrospektif olarak değerlendirdik. Materyal ve Metod: Çalışmamızda Ankara Numune Eğitim ve Araştırma Hastanesinde İTP takipli 116 hastanın dosyası incelenmiştir. Bu çalışmada İTP hastalarının cinsiyetlerine, tanı yaşlarına ve atak zamanlarına, aldıkları tedavilere, kanama öykülerine, laboratuvar parametrelerine (Plt,HGB...), megakaryosit ve kemik iliği incelemelerine, Helicobacter pylori pozitifliğine ve atak zamanlarına bakılmıştır. Bulgular: İTP tanısı ile değerlendirilen 116 hastanın 80'i kadın, 36'sı erkekti (K/E:2,2). Tanı anında olguların yaş ortalaması 43 (Aralık; 17-86) idi. Olguların başlangıç trombosit değerleri 1x109/L ile 100x109/L arasında değişmekteydi (ortalama 46,6x109/L). 25 olgu kanama (burun, ağız, idrar, menoraji, gastrointestinal kanama) ile başvurdu. Olguların 91'inde kanama bulgusu saptanmadı. Splenektomi işlemi 29 ( %25) hastaya uygulandı. Helicobacter pylori saptanan hasta sayısı 22 (%19) olarak saptandı. Helicobacter pylori pozitifliğinin, kanama, trombositopenik atak sayısı, tanı anındaki trombosit sayısı ile ilişkisi saptanmadı. Trombosit değeri bir defa 30x109/L altında olan hasta sayısı 41(35,3), 2 olan hasta sayısı 25 (%21,6) olduğu gözlendi. Trombositopenik atak sayısı kadın/erkek oranı ( 3,29) olarak saptandı. Kadın hastalarda trombositopenik atak sayısının daha fazla olduğu, tanı anındaki trombosit değerinin daha düşük olduğu istatiksel olarak anlamlı bulundu (p<0,005). Kadınlarda kanamanın daha sık olduğu gözlendi. Tanı anında trombosit sayısı düşük olan hastalarda trombositopenik atak sayısının ve kanamasının daha fazla olduğu istatiksel olarak anlamlı bulundu (p<0,05). Trombositopeni atağının en sık yaz mevsiminde (%33) ortaya çıktığı gözlendi ancak istatiksel olarak anlamlı değildi. Tartışma: Diğer otoimmün hastalıklarda olduğu gibi İTP de kadın cinsiyette sık görülmektedir bu diğer çalışmalarda da gösterilmiştir. Bunun nedeni tam olarak aydınlanmasa da hormonlar, çevresel faktörler, genetik sebepler suçlanmıştır. Bugün en çok kabul edilen görüş X kromozomu kontrolündeki genlerin inflamasyon ve immüniteyle ilişkisine bağlanmıştır. Çalışmamızda İTP'nin kadınlarda daha sık görüldüğü aynı zamanda kadın cinsiyette kanamanın ve atak sayısının belirgin yüksek olduğu bulunmuştur. Bu hasta grubunun trombositopenik atak sayısı ve kanama açısından yakın takip edilmesi gerekir. Sonuç: Diğer otoimmün hastalıklarda olduğu gibi İTP de kadın cinsiyette sık görülmektedir bu diğer çalışmalarda da gösterilmiştir. Bunun nedeni tam olarak aydınlanmasa da hormonlar, çevresel faktörler, genetik sebepler suçlanmıştır. Bugün en çok kabul edilen görüş X kromozomu kontrolündeki genlerin inflamasyon ve immüniteyle ilişkisine bağlanmıştır. Çalışmamızda İTP'nin kadınlarda daha sık görüldüğü aynı zamanda kadın cinsiyette kanamanın ve atak sayısının belirgin yüksek olduğu bulunmuştur. Bu hasta grubunun trombositopenik atak sayısı ve kanama açısından yakın takip edilmesi gerekir. [ABSTRACT FROM AUTHOR]
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.